Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26815111 | 0.83 | PRKCI (0.50) | PRKCICYP2A6CHRNA7CYP19A1FAAH | |
| SCHEMBL18876154 | 0.81 | PRKCI (0.52) | PRKCICYP2A6CHRNA7CYP19A1FAAH | |
| SCHEMBL3772060 | 0.80 | PRKCI (0.41) | PRKCICYP2A6CHRNA7CYP19A1TRPA1 | |
| SCHEMBL30046101 | 0.79 | PRKCI (0.50) | PRKCICYP2A6CHRNA7CYP19A1FAAH | |
| SCHEMBL20562931 | 0.79 | PRKCI (0.59) | PRKCICYP2A6CHRNA7FAAHHSD11B1 | |
| SCHEMBL28909178 | 0.79 | PRKCI (0.50) | PRKCICYP2A6CHRNA7CYP19A1FAAH | |
| SCHEMBL14402849 | 0.79 | PRKCI (0.50) | PRKCICYP2A6CHRNA7FAAHTRPA1 | |
| SCHEMBL30510384 | 0.78 | GRIK1 (0.48) | PRKCICYP2A6CHRNA7FAAH | |
| SCHEMBL25186563 | 0.78 | GRIK1 (0.48) | PRKCICYP2A6CHRNA7FAAH | |
| SCHEMBL25186562 | 0.78 | GRIK1 (0.48) | PRKCICYP2A6CHRNA7FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | PRKCI 1107/4885CYP2A6 2681/4885CHRNA7 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.